|Day Low/High||68.42 / 68.75|
|52 Wk Low/High||60.89 / 85.97|
I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.
Trading action has been jumpy, so where's the trend?
Over the past month, 3 sectors have revealed themselves as market leaders: Technology, Healthcare and Consumer Staples.
The presidential task force wasn't going to address the media Sunday. Then, they did. Actual news? Futures markets opened ahead of that, in the green, and went higher. That's interesting.
For March and the first quarter, the RMPIA takes less of a hit than major indexes.
The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
Things will be different after Covid-19 and one change will be in how people care about themselves.
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
Consider these stock model ideas: virus groups, work remotely, and fiscal.
The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.
The next four to six weeks could determine whether the U.S. economy can recover from the coronavirus crisis without lasting damage
Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.
I continue to shuttle new money into the market on declines using buy-write option strategies.
Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
The market has gained some momentum. It looks like the administration might be readying to declare a national emergency. The president is scheduled to make comments starting an hour before the market close. I expect equities to continue to be volati...
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
Markets look like they will see a substantial rebound today, at least in the early going. S&P 500 futures are up some 5% just before the market opens. Gilead Sciences just reported encouraging results around its experimental antiviral Remdesivir in...
Right now, GILD holds a strictly defensive spot among my holdings.
What came first? The chicken or the egg? The bear market or the pandemic? I don't care much for labels.
There are small vaccine and testing companies that see their shares spike when a new virus hits, but whether those gains will last is questionable.
The question begs... 'Do significantly lower oil prices provoke increased demand?' Anywhere?
But don't throw up your arms yet -- here are names that could be golden opportunities.
I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.
Here are a number of things that I'm watching now.
Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.